NanoVibronix, Inc. (NASDAQ:NAOV) Short Interest Update

NanoVibronix, Inc. (NASDAQ:NAOV) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 34,700 shares, a drop of 17.4% from the May 31st total of 42,000 shares. Based on an average daily trading volume, of 38,800 shares, the days-to-cover ratio is presently 0.9 days. Currently, 1.3% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NanoVibronix stock. Armistice Capital LLC acquired a new stake in shares of NanoVibronix, Inc. (NASDAQ:NAOV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 29,023 shares of the company’s stock, valued at approximately $57,000. Armistice Capital LLC owned about 1.75% of NanoVibronix at the end of the most recent reporting period. 16.39% of the stock is currently owned by hedge funds and other institutional investors.

NanoVibronix Price Performance

NAOV stock traded up $0.02 during trading on Tuesday, reaching $0.72. 36,717 shares of the stock traded hands, compared to its average volume of 69,794. NanoVibronix has a 52-week low of $0.67 and a 52-week high of $4.23. The business’s 50 day moving average price is $0.76 and its 200-day moving average price is $0.89.

NanoVibronix (NASDAQ:NAOV) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.23) earnings per share for the quarter. The company had revenue of $0.92 million during the quarter. NanoVibronix had a negative return on equity of 95.96% and a negative net margin of 112.35%.

NanoVibronix Company Profile

NanoVibronix, Inc, through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.